17 completed. 17 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 17 |
| Phase 2 | 1 | Completed 1 |
Follow Anaemia: new trials by email Literature Review of Anaemia trials Research Report on Anaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients. Erythropoietin + Probiotic, EPO - Anaemia, Chronic Kidney Disease | Phase 3 | Completed | Badr University | 80 | 2026-02-01 | 2026-10-30 |
| Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) Daprodustat - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 4 | 2023-09-06 | 2025-11-10 |
| Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD) Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 407 | 2018-09-05 | 2021-07-12 |
| Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) Daprodustat (GSK1278863), Placebo, Iron therapy - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 614 | 2018-03-05 | 2024-04-02 |
| Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Daprodustat, Darbepoetin alfa, Iron therapy - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 312 | 2017-05-11 | 2021-10-20 |
| A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) Daprodustat small, Daprodustat small placebo, Daprodustat large - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 271 | 2016-11-21 | 2020-11-27 |
| Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Daprodustat, rhEPO, Placebo - Anaemia, Aspergillosis, Allergic Bronchopulmonary | Phase 3 | Completed | GlaxoSmithKline | 2964 | 2016-09-28 | 2021-12-03 |
| Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Daprodustat, Darbepoetin alfa, Placebo - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 3872 | 2016-09-27 | 2024-04-02 |
| Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents GSK1278863, Iron - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 28 | 2016-08-08 | 2019-12-03 |
| Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia 1 to 4 mg tablets of GSK1278863, 6 mg GSK1278863 tablet, Epoetin beta pegol - Anaemia | Phase 3 | Completed | GlaxoSmithKline | 355 | 2016-06-06 | 2021-05-18 |
| Safe and Efficacious Iron for Children in Kenya Low-dose iron as NaFeEDTA, Conventional dose iron as ferrous salt, Placebo - Anaemia | Phase 2 / Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 338 | 2014-06-01 | 2015-04-10 |
| Preoperative Intravenous Iron to Treat Anaemia in Major Surgery Ferric carboxymaltose, Normal saline - Anaemia | Phase 3 | Completed | University College, London | 487 | 2014-01-01 | 2019-06-03 |
| Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease Monofer - Inflammatory Bowel Disease, Anaemia | Phase 3 | Completed | Pharmacosmos A/S | 39 | 2011-06-01 | 2013-11-26 |
| Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women ferrous sulphate, Ferinject - Anaemia | Phase 3 | Completed | Vifor Pharma | 252 | 2010-05-01 | 2015-05-29 |
| Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea chloroquine, sulphadoxine pyrimethamine, LLIN, azithromycin, sulphadoxine pyrimethamine, LLIN - Malaria in Pregnancy, Sexually Transmitted Infections | Phase 3 | Completed | University of Melbourne | 2793 | 2009-11-01 | 2013-04-23 |
| Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) Ferinject ® (Ferric carboxymaltose), Normal saline (0.9%) - Chronic Heart Failure, Iron Deficiency | Phase 3 | Completed | Vifor Pharma | 456 | 2007-04-01 | 2021-10-14 |
| Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine - Malaria, Anaemia | Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 3333 | 2007-02-01 | 2016-10-20 |
Anemia (17) · Renal Insufficiency, Chronic (8) · Iron Deficiencies (2) · Anemia, Iron-Deficiency (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Heart Diseases (1) · Inflammatory Bowel Diseases (1) · Kidney Failure, Chronic (1) · Malaria (1) · Malaria, Falciparum (1) · Malaria, Vivax (1) · Sexually Transmitted Diseases (1) · Treponemal Infections (1)
Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Disease Attributes (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Urogenital Diseases (9) · Chronic Disease (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Kidney Diseases (8) · Male Urogenital Diseases (8) · Renal Insufficiency (8) · Urologic Diseases (8) · Infections (3) · Bacterial Infections and Mycoses (2)
GSK1278863 (8) · Darbepoetin alfa (3) · Iron (3) · ferric carboxymaltose (3) · Saline Solution (2) · fanasil, pyrimethamine drug combination (2) · Amodiaquine (1) · Azithromycin (1) · Chloroquine (1) · Erythropoietin (1) · Fe(III)-EDTA (1) · Probiotics (1) · continuous erythropoietin receptor activator (1) · ferrous sulfate (1)
GlaxoSmithKline (9) · London School of Hygiene and Tropical Medicine (2) · Vifor Pharma (2) · Badr University (1) · Pharmacosmos A/S (1) · University College, London (1) · University of Melbourne (1)
Argentina (6) · Australia (6) · Italy (6) · Poland (6) · Russia (6) · South Korea (6) · Spain (6) · United Kingdom (6) · Canada (5) · Germany (5) · Romania (5) · United States (5) · Brazil (4) · France (4) · Japan (4)
Brian Greenwood, MD (1) · Christian Breymann (1) · Daniel Chandramohan, PhD (1) · Edmund Browne, PhD (1) · Hans Verhoef, PhD (1) · Harry Tagbor, DrPH (1) · Jane Bruce, MSc (1) · Philip A Poole-Wilson, MD FRCP (1) · Stephen J Rogerson, FRACP PhD (1) · Toby Richards, MD FRCS (1)
PMID 36005278, PMID 36565721, PMID 38383961, PMID 19875408, PMID 19920054, PMID 21203389, PMID 25591391, PMID 26006260, PMID 26041028, PMID 26286026, PMID 28103875, PMID 28449690, PMID 28770094, PMID 29391008, PMID 33561857, PMID 33632377, PMID 33744933, PMID 34181872, PMID 34607575, PMID 34739194, PMID 35377393, PMID 35619134, PMID 35918106, PMID 36739866
2016 (3), 2017 (2)